Ultrasound Synovitis Offers Potential Treatment Strategy for Patients with Rheumatoid Arthritis and Fibromyalgia

Ultrasound Synovitis Offers Potential Treatment Strategy for Patients with Rheumatoid Arthritis and Fibromyalgia
pharmacyFindings from a recent study published in the journal PLoS One found that ultrasound synovitis (US) scores are not affected by Fibromyalgia in patients with Rheumatoid Arthritis, with researchers indicating that US may be a potential treatment strategy for these patients. Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by erosive synovitis, responsible for bone and cartilage damage. The condition is usually treated with disease modifying antirheumatic drugs (DMARDs) to prevent joint destruction. Fibromyalgia (FM) is a chronic pain condition accompanied by somatic symptoms such as fatigue and sleep disorders. FM is present in up to 20% of RA patients and may increase subjective components of disease activity indexes, misleading treatment decision. FM-induced overestimation of RA activity may cause overtreatment as DMARDs are changed to achieve the target and undertreatment as physicians aware of FM impact on clinical scores may not change DMARD when truly necessary. Ultrasound (US) is an objective synovitis assessment tool that is able to predict joint destruction. Gray-scale (GSUS) and power Doppler ultrasound (PDUS) are capable of measuring synovial proliferation and vascularization. The validated 7-joint score (US7)
Subscribe or to access all post and page content.